PRESS RELEASE published on 06/10/2025 at 10:06, 1 year 3 months ago Edison issues report on BB Biotech (BION) Edison issues report on BB Biotech (BION) covering the recent challenges and opportunities in the biotech sector, including market volatility and long-term outlook Edison Market Volatility Biotech Sector BB Biotech Long-term Outlook
BRIEF published on 04/25/2025 at 07:05, 1 year 4 months ago BB Biotech AG Reports CHF 241 Million Net Loss for Q1 2025 Drug Development Net Loss Investment Portfolio Interim Report BB Biotech
BRIEF published on 04/25/2025 at 07:05, 1 year 4 months ago BB Biotech AG annonce une perte nette de 241 millions de francs suisses au premier trimestre 2025 Perte Nette Portefeuille D'investissement Développement De Médicaments BB Biotech Rapport Intermédiaire
BRIEF published on 04/25/2025 at 07:05, 1 year 4 months ago BB Biotech Q1 2025: Portfolio Adjustments Amid Volatile Market Market Volatility Investment Portfolio Biotech Sector BB Biotech FDA Approvals
BRIEF published on 04/25/2025 at 07:05, 1 year 4 months ago BB Biotech T1 2025 : ajustements de portefeuille dans un contexte de marché volatil Volatilité Du Marché Portefeuille D'investissement BB Biotech Secteur Biotechnologique Approbations De La FDA
PRESS RELEASE published on 04/25/2025 at 07:00, 1 year 4 months ago EQS-Adhoc: BB Biotech AG publishes its interim report BB Biotech AG publishes its interim report covering the first three months of 2025 revealing a net loss of CHF 241 mn. More information at report.bbbiotech.ch/Q125 Financial Results Investment Company BB Biotech AG Interim Report Business Activities
PRESS RELEASE published on 04/25/2025 at 07:00, 1 year 4 months ago BB Biotech Q1 2025: Sharpened portfolio focus amid continued market volatility BB Biotech AG reports net loss in Q1 2025 due to market volatility. Portfolio focus on innovative biotech companies above USD 1 bn. Details on exits and regulatory milestones Market Volatility BB Biotech AG Biotech Companies Q1 2025 Portfolio Focus
BRIEF published on 03/19/2025 at 17:50, 1 year 5 months ago BB Biotech AG Shareholders Approve Dividend and Re-Elect Board Investment Strategy Dividend Board Re-election BB Biotech AGM 2025
BRIEF published on 03/19/2025 at 17:50, 1 year 5 months ago Les actionnaires de BB Biotech AG approuvent le dividende et réélisent le conseil d'administration Dividende Stratégie D'investissement Réélection Du Conseil D'administration BB Biotech Assemblée Générale Annuelle 2025
PRESS RELEASE published on 03/19/2025 at 17:45, 1 year 5 months ago Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share Shareholders at BB Biotech AG’s AGM approve dividend of CHF 1.80 per share and all board proposals. Re-elected board members for another term Shareholders Dividend AGM BB Biotech AG Board Proposals
Published on 09/12/2026 at 02:35, 11 hours 44 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 19 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 14 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 54 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 19 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 48 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 16 hours 3 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 16 hours 8 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 34 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 20 hours 3 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
